Skip to main content

Table 2 Characteristics of the 1087 GB patients included

From: The French glioblastoma biobank (FGB): a national clinicobiological database

Patients included in the FGB

Number

%

Patient characteristics

 Age (median age: 63 years)

  

  < 70 years

801

73.7

  ≥ 70 years

286

26.3

 Sex

  Male

653

60.1

  Female

434

39.9

 KPS score

  ≥ 70

601

55.3

  < 70

73

6.7

  Missing data

413

38.0

 Risk factors

  No relevant exposure

549

50.5

  Relevant exposure

124

11.4

    Family history of brain tumors

46

4.2

    Electromagnetic fields

19

1.7

    Petrochemical exposure

16

1.5

    Pesticide exposure

55

5.1

    Other (e.g. chemical products, asbestos, lead)

42

3.9

  Missing data

414

38.1

 OS

  Median (24.2 months)

915

84.2

  Short (< 6 months)

100

9.2

  Long (> 3 years)

61

5.6

  Missing data

172

15.8

Tumor characteristics

 Tumor location

  Unilobar

454

41.8

    Frontal lobe

166

15.3

    Temporal lobe

169

15.5

    Parietal lobe

91

8.4

    Occipital lobe

18

1.7

    Corpus callosum

8

0.7

    Cerebellum

2

0.2

  Multilobar

485

44.6

  Missing data

148

13.6

 2016 WHO CNS classification

  GB IDH-wildtype

937

86.2

    Giant cell GB

35

3.2

    Gliosarcoma

8

0.7

  GB IDH-mutant

62

5.7

  GB NOS

88

8.1

 MGMT status

  Unmethylated

209

19.2

  Methylated

201

18.5

  Missing data

677

62.3

First-line treatment

 Type of surgery

  Biopsy

145

13.3

    Surgical biopsy

35

3.2

    Stereotactic biopsy

106

9.8

    Missing data

4

0.4

  Resection [total, subtotal (≥ 90%) or partial (< 90%)]

797

73.3

  Lobectomy

9

0.8

  Missing data

136

12.5

 Surgical technique/per-operatory treatment

  Awake craniotomy

67

6.2

  5-ALA fluorescence

78

7.2

  Gliadel wafer

67

6.2

 Adjuvant therapy

  Without adjuvant therapy

46

4.2

  Radiotherapy alone

25

2.3

  Radiotherapy/TMZ

624

57.4

  Avastin (± radiotherapy/TMZ)

45

4.1

  Gliadel wafer (± radiotherapy/TMZ)

65

6.0

  Other chemotherapy

18

1.7

  Missing data

177

16.3

Second-line treatment

 Surgery (± radio/chemotherapy)

105

9.7

 Treatment without surgery

545

50.1

  1. 5-ALA 5-aminolevulinic acid, IDH isocitrate dehydrogenase, KPS Karnofsky performance status, MGMT O6-methylguanine-DNA methyltransferase, NOS not otherwise specified, OS overall survival